Boehringer Ingelheim Enrolls First Patient in Phase III Trial of BI 1015550 in Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim announced that the first patient has enrolled in FIBRONEER^TM-IPF, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).